- Home
- XPON vs ADXN Comparison
XPON vs ADXN Comparison
Compare XPON & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPON | ADXN |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 10.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | XPON | ADXN |
|---|---|---|
| Price | $0.89 | $7.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 216.9K | 3.1K |
| Earning Date | 11-13-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,417,947.00 | $198,824.00 |
| Revenue This Year | $61.26 | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 109.37 | N/A |
| 52 Week Low | $0.60 | $6.51 |
| 52 Week High | $5.50 | $12.05 |
Technical Indicators
Market Signals| Indicator | XPON | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 45.86 |
| Support Level | $0.66 | $7.72 |
| Resistance Level | $1.26 | $8.90 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 74.81 | 16.08 |
Price Performance
Historical ComparisonAbout XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.